Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open

• Published in: Alimentary pharmacology & therapeutics 2022-06, Vol.55 (12), p.1534-1544
• Main Authors: Panaccione, Remo, Abreu, Maria T., Lazariciu, Irina, Mundayat, Rajiv, Lawendy, Nervin, Salese, Leonardo, Woolcott, John C., Sands, Bruce E., Chaparro, María
• Format: Article
• Language: English
• Subjects: Colitis, Ulcerative - chemically induced; Colitis, Ulcerative - drug therapy; Drug dosages; Enzyme inhibitors; Humans; Inflammatory bowel disease; Janus kinase; Longitudinal Studies; Original; Patients; Piperidines - therapeutic use; Pyrimidines - therapeutic use; Pyrroles - therapeutic use; Remission; Survival; Tofacitinib in Ulcerative Colitis; Ulcerative colitis
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/apt.16848

Summary Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aim This post hoc analysis evaluated tofacitinib persistence in patients with UC in OCTAVE Open, an open‐label, long‐term extension study of patients receiving tofacitinib 5 or 10 mg twice daily. Methods Kaplan‐Meier estimates for tofacitinib drug survival and reasons for discontinuations were evaluated. Baseline factors were analysed as predictors of persistence. Results This analysis included 603 patients: 280 entered OCTAVE Open with a clinical response (164 in remission and 116 not in remission), 220 were delayed responders, 75 were retreatment responders and 35 were dose escalation responders, treated for up to 7 years in OCTAVE Open. Of these, 118 (42.1%) responders, 121 (55.0%) delayed responders, 40 (53.3%) retreatment responders and 17 (48.6%) dose escalation responders discontinued tofacitinib with a median time to discontinuation of 5.6, 4.5, 4.0 and 4.4 years, respectively. The estimated 2‐ and 5‐year drug survival rates in the responders (including patients in remission and not in remission) were 73.9% and 54.5%, respectively. Corresponding persistence values for delayed responders were 69.5% and 45.2%, for retreatment responders, 70.7% and 40.0%, and for dose escalation responders, 74.3% and 32.8%. Conclusion In OCTAVE Open, a high proportion of patients maintained tofacitinib treatment, with the median survival by group ranging from 4.0 to 5.6 years although these analyses are post hoc and limited by sample size. Further research should focus on factors to enhance persistence with tofacitinib treatment in patients with UC.